Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Boehringer Ingelheim Adds $149 Million to its Investment in China

publication date: Oct 23, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Boehringer Ingelheim of Germany will invest $149 million in China with the goal of increasing its market share in China’s pharmaceutical market. The company will use the money to expand the capacity at its existing drug production facility in Shanghai's Zhangjiang High-Tech Park, and it will also establish an R&D facility. More details...

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...